The Massachusetts Prescription Awareness Tool (MassPAT), our new Online Prescription Monitoring Program (PMP), is now live! For more information, including how to register and access MassPAT, please follow this link to the PMP website: www.mass.gov/dph/dcp/pmp.
FDA Recall Notice Re: Teva Pharmaceuticals (8/15/16) Recalls Seven Lots of Amikacin Sulfate Injection USP
Teva Pharmaceuticals of North Wales, PA, has recalled seven lots of amikacin sulfate injection, USP, 500 mg/2 mL (250 mg/mL) and 1 gram/4 mL (250 mg/mL) vials because of the potential for the presence of glass particulate matter. Amikacin sulfate injection 250 mg/mL, 2 mL and 4 mL vials were distributed nationwide through wholesalers, retailers, and pharmacies. The specific lot numbers, expiration dates, and national drug code numbers can be found in the recall alert posted to FDA’s website. To date, Teva has not received any reports of adverse events or complaints related to this recall. Anyone with an existing inventory of the recalled lots should stop use and distribution and quarantine the product immediately. Adverse events or quality issues can be reported to FDA’s MedWatch Safety Information and Adverse Event Reporting Program.
The Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA) (FDA), health departments and multiple healthcare facilities continue to investigate a multi-state outbreak of infections caused by Burkholderia cepacia complex (also known as “B. cepacia complex”). To date, CDC has confirmed 60 cases from 8 states.
On August 10, 2016 CDC released a statement (below and linked) regarding a voluntary recall (http://www.fda.gov/Drugs/DrugSafety/ucm511527.htm) of all liquid products manufactured by PharmaTech and distributed by: Rugby, Major, Bayshore, Metron, Centurion, and Virtus.
The Department will continue to provide updates as additional information is made available by CDC. Cases of Burkholderia cepacia should be reported to the Massachusetts Department of Public Health at 617-983-6800. Please contact Eileen McHale at Eileen.email@example.com if you have questions regarding this message.
Additional information about Burkholderia cepacia and the outbreak is available on the CDC website at the following links:
Important information regarding new MA driver's licenses and IDs
The Massachusetts Prescription Awareness Tool (MassPAT) will go live August 22, 2016. Online registration for MassPAT is now open. Users will not be able to conduct patient searches in MassPAT until August 22, 2016. For more information, including accessing MassPAT, please follow this link to the Prescription Monitoring Program (PMP) website: http://www.mass.gov/dph/dcp/pmp
New Pharmacist Continuing Education (CE) Requirements
As of January 1, 2015, CE requirements have changed for all pharmacists registered in Massachusetts. Pharmacists are now required to complete twenty (20) CE hours per calendar year.
Please see the following attachments for more detailed information regarding pharmacist CE requirements.
- Information on mission, activity, membership, calendar, agenda and emergency and holiday closures.
- Includes applications and forms.
Information concerning the fungal meningitis outbreak and subsequent investigation, NECC product recall and related materials for health care providers and press.